The DOI matches its Crossref record; 426 of the 435 references it cites were found in a registry or an index.
From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases
Abstract
The functional and structural versatility of Ribonucleic acids (RNAs) makes them ideal candidates for overcoming the limitations imposed by small molecule-based drugs. Hence, RNA-based biopharmaceuticals such as messenger RNA (mRNA) vaccines, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNA mimics, anti-miRNA oligonucleotides (AMOs), aptamers, riboswitches, and CRISPR-Cas9 are emerging as vital tools for the treatment and prophylaxis of many infectious diseases. Some of the major challenges to overcome in the area of RNA-based therapeutics have been the instability of single-stranded RNAs, delivery to the diseased cell, and immunogenicity. However, recent advancements in the delivery systems of in vitro transcribed mRNA and chemical modifications for protection against nucleases and reducing the toxicity of RNA have facilitated the entry of several exogenous RNAs into clinical trials. In this review, we provide an overview of RNA-based vaccines and therapeutics, their production, delivery, current advancements, and future translational potential in treating infectious diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unmodified mRNAs can trigger inflammation and immune reactions when introduced into the body as foreign invaders, thus compromising efficacy and safety [52].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [52]
Citations
Cites
Items 401–426 of 426
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Ferro, C. J., Sarafidis, P., & Ortíz, A. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004861 · Cited by 21
Are Viral Vectors Any Good for RNAi Antiviral Therapy?
Lundstrom, K. H. (2020) · Viruses · doi:10.3390/v12101189 · Cited by 21
Pasi, J., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T. J., Bevan, D. H., Austin, S. K., Hay, C. R. M., Brand, B., Kazmi, R. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.551.551 · Cited by 20
de Campos, W. R. L., Chirwa, N., London, G. M., Rotherham, L. S., Morris, L., Mayosi, B. M., & Khati, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110930 · Cited by 19
Nazari, R., Zhong, X. Y., & Joshi, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001222-0 · Cited by 19
Kubo, T., Yanagihara, K., Takei, Y., Mihara, K., Sato, Y., & Seyama, T. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.128 · Cited by 19
Berk, C., Civenni, G., Wang, Y., Steuer, C., Catapano, C. V., & Hall, J. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0852 · Cited by 19
Motard, J., Rouxel, R. N., Paun, A., von Messling, V., Bisaillon, M., & Perreault, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027327 · Cited by 18
Multilayer fluorescence optically encoded beads for protein detection
Jun, B., Rho, C., Byun, J., Kim, J., Chung, W., Kang, H., Park, J. Y., Cho, S., Kim, B., & Lee, Y. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.052 · Cited by 18
Um, H., Kim, M. K., Lee, S., & Kim, Y. (2012) · AIDS · doi:10.1097/qad.0b013e3283554f7d · Cited by 18
Gonzalez-Carmona, M.-A., Schüssler, S., Serwe, M., Alt, M., Ludwig, J., Sproat, B. S., Steigerwald, R., Hoffmann, P., Quasdorff, M., Schildgen, O., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.022 · Cited by 17
Roh, C., Kim, S. E., & Jo, S. (2011) · Sensors · doi:10.3390/s110706685 · Cited by 16
Chowdhury, S. K., Burris, H. A., Patel, M., Infante, J. R., Jones, S. F., Voskoboynik, M., Parry, K., Elvin, P., Coleman, T., Gardner, H., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)33031-3 · Cited by 16
Engineered RNase P Ribozymes Effectively Inhibit the Infection of Murine Cytomegalovirus in Animals
Li, W., Liu, Y., Wang, Y., Li, R., Trang, P., Tang, W. F., Yang, Z., Wang, Y., Sun, X., Xing, X., et al. (2018) · Theranostics · doi:10.7150/thno.27776 · Cited by 16
Lorenzer, C., Streußnig, S., Tot, E., Winkler, A.-M., Merten, H., Brandl, F., Sayers, E. J., Watson, P., Jones, A. T., Zangemeister‐Wittke, U., et al. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.015 · Cited by 16
Sørensen, B., Mant, T., Akinc, A., Simon, A. R., Melton, L., Lynam, C., Strahs, A. L., Sehgal, A., Hutabarat, R. M., Chaturvedi, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.693.693 · Cited by 15
Kupersmith, M. J., & Miller, N. R. (2016) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000409 · Cited by 15
Antiviral treatment strategies based on gene silencing and genome editing
Badía, R., Ballana, E., Esté, J. A., & Riveira‐Muñoz, E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.04.001 · Cited by 15
Cullen, B. R. (2007) · Science · doi:10.1126/science.1146077 · Cited by 14
Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch
Xu, H., Tong, X., Mugundu, G. M., Scott, M. L., Cook, C., Arfvidsson, C., Pease, E. J., Zhou, D., Lyne, P. D., & Al-Huniti, N. H. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09619-6 · Cited by 13
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
Leibundgut, E. O., Haubitz, M., Burington, B. E., Ottmann, O. G., Spitzer, G., Odenike, O. M., McDevitt, M. A., Röth, A., Snyder, D., & Baerlocher, G. M. (2020) · Haematologica · doi:10.3324/haematol.2020.252817 · Cited by 12
Single Ascending Dose Study in Participants With LCA10
(2019) · Case Medical Research · doi:10.31525/ct1-nct03872479 · Cited by 11
Nawtaisong, P., Fraser, M. E., Carter, J. R., & Fraser, M. J. (2015) · Virology · doi:10.1016/j.virol.2015.02.023 · Cited by 7
de Jong, W., Aerts, J. L., Allard, S. D., Brander, C., Buyze, J., Florence, É., Gorp, E. C. M. V., Vanham, G. L., Leal, L., Mothe, B., et al. (2019) · Trials · doi:10.1186/s13063-019-3940-0 · Cited by 7
Ulmer, J. B., Wahrén, B., & Liu, M. A. (2006) · Current Opinion in HIV and AIDS · doi:10.1097/01.coh.0000232346.08285.a8 · Cited by 6
[Antisense oligonucleotides--a new generation of potential drugs].
He, M. (1995) · PubMed · Cited by 1
Flagged first, then by citations
9 of the 435 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Antoszyk, 2013, A phase I open label, dose escalation trial of QPI-1007 delivered by A single intravitreal (IVT) injection to subjects with low visual acuity and acute non-arteritic anterior ischemic optic neuropathy (NAION), Invest. Ophthalmol. Vis. Sci., 54, 4575
- Baden, 2020, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N. Engl. J. Med.
Cited by
Sorted by citations
Exosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
Bian, X., Zhou, L., Luo, Z., Liu, G., Hang, Z., Li, H., Li, F., & Wen, Y. (2025) · ACS Nano · doi:10.1021/acsnano.4c11858 · Cited by 101
Using aptamers for targeted delivery of RNA therapies
Driscoll, J., Gondaliya, P., Zinn, D. A., Jain, R., Yan, I. K., Dong, H., & Patel, T. C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.047 · Cited by 69
mRNA vaccines: a new era in vaccine development
Chandra, S., Wilson, J. C., Good, D. M., & Wei, M. Q. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.043987 · Cited by 58
Dai, B., Zhu, Y., Li, X., Liang, Z., Xu, S., Zhang, S., Zhang, Z., Bai, S., Tong, W., Cao, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300897 · Cited by 45
Metadata
- Authors
- Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G.
- Affiliations
- Regional Centre for Biotechnology (IN)
- Corresponding author
- Rode, Ambadas B.
- Chawla, Geetanjali
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 81
- Pages
- 101003
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W3185845179
- Cited by
- 23
- References
- 435
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 3 · 2021: 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Molecular Aspects of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Science and Technology, Ministry of Science and Technology, India (IA/I(S)/17/1/503085)
- The Wellcome Trust DBT India Alliance (IA/I(S)/17/1/503085)
- Department of Biotechnology, Ministry of Science and Technology, India (IA/I(S)/17/1/503085)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- RNA therapeutics, RNA vaccines, infectious diseases, mRNA vaccines, antisense oligonucleotides, siRNA, miRNA mimics, antagomir, aptamers, riboswitches, CRISPR/Cas9, RNA delivery systems, RNA modification, immunogenicity, translational medicine, clinical trials
- MeSH terms
- mRNA Vaccines, Communicable Diseases, Humans, Oligonucleotides, Vaccines, Synthetic, Oligonucleotides, Antisense, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
